INTS Intensity Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:40
Jan 08
Jan 08
Non-covalent tumor injection platform shows efficacy; potential acquisition target
The author argues INTS's INT230-6 combines already approved oncology drugs with a non-covalent delivery molecule, preserving predictable pharmacology. Preliminary TNBC results show higher efficiency and 50% fewer safety issues than standard of care. The DfuseRx platform could revive shelved toxic drugs and makes INTS an acquisition target.
HIGH
About INTS Investor Commentary
Across the available history and selected sources, Buzzberg tracks INTS (Intensity Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/BearWithMeGM.